Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma  by Watzka, Stefan B. et al.
G
T
S
General Thoracic Surgery Watzka et alDetection of integrin-linked kinase in the serum of patients with
malignant pleural mesotheliomaStefan B. Watzka, MD,a,b Florian Posch, Cand.Med.,b,c Harvey I. Pass, MD,d Margaret Huflejt, PhD,d
David Bernhard, PhD,c Gregory E. Hannigan, PhD,e and Michael R. M€uller, MD, PhDa,bFrom th
racic
search
Vienn
Lango
Cance
Melb
Specime
suppo
to H.I
Disclosu
Receive
public
Address
Lands
atoriu
0022-52
Copyrig
doi:10.1
384Objective: Integrin-linked kinase, which is relevant to neoplastic transformation, is highly expressed in malig-
nant pleural mesothelioma. Recently, detection of integrin-linked kinase in serum of patients with ovarian cancer
has been reported. This study asks whether integrin-linked kinase can also be detected in serum of patients with
malignant pleural mesothelioma and whether serum level has diagnostic or prognostic relevance for that disease.
Methods: A sandwich enzyme-linked immunosorbent assay was designed to detect integrin-linked kinase and
applied to serum samples from 46 patients with malignant pleural mesothelioma, 98 patients with other malig-
nant chest disease, and 23 patients with benign chest disease. Integrin-linked kinase serum concentration and
clinical data were correlated statistically.
Results:Median serum integrin-linked kinase concentration was significantly higher in malignant pleural meso-
thelioma (8.89 ng/mL) than in other malignant chest disease (0.66 ng/mL) or benign chest disease (0.78 ng/mL,
P<.001). Therewas no relevant correlation of serum integrin-linked kinasewith cell lysis parameters (R2<0.1).
Serum integrin-linked kinase concentration greater than 2.48 ng/mL had diagnostic sensitivity of 80%, specific-
ity of 95%, positive predictive value of 85.7%, negative predictive value of 92.7%, and overall accuracy of 91%
for distinction between malignant pleural mesothelioma and other diseases. Serum integrin-linked kinase
concentration in malignant pleural mesothelioma was independent of histologic subtype or asbestos exposure.
There was no statistically significant impact of serum integrin-linked kinase concentration on prognosis.
Conclusions: Integrin-linked kinase can be detected in serum of patients with malignant pleural mesothelioma
and may be a diagnostic marker for the disease. (J Thorac Cardiovasc Surg 2011;142:384-9)Malignant pleural mesothelioma (MPM) is a tumor derived
from the mesodermal pleural layers that is mostly associ-
ated with asbestos exposure. Clinically, MPM is character-
ized by aggressive local spread, few or nonspecific
symptoms at early stages, low response to cytostatic drugs1
and radiation, and a particularly poor prognosis.2 Despite
intense multimodality therapy efforts,3-5 outcomes have
not considerably improved, because most patients are
seen with already advanced disease. Early detection by
reliable biomarkers may thus be a valuable strategy to
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The Journal of Thoracic and Cardiovascular SurgChronic inflammation of the pleura is the basic pathoge-
netic principle of MPM.6 One molecule that has been
implicated with chronic inflammatory processes is
integrin-linked kinase (ILK), an intracellular serine/threo-
nine kinase that links b-integrins to the cytoskeleton.7 In
addition to being required for inflammatory responses,8
ILK can (when overexpressed) induce an epithelial–
mesenchymal transition and a tumorigenic phenotype in
epithelial cells.9 Conversely, inhibition of ILK exerts anti-
neoplastic effects.10 We first showed that ILK is highly ex-
pressed in 90% of MPM samples, regardless of the
histologic subtype, whereas healthy pleural and lung tissue
does not express ILK at all.11,12 Support for a specific role
of ILK in MPM biology comes from a recent study that
shows that increased expression of kindlin-2 (an integrin-
interacting focal adhesion protein of the kindlin family)
at the MPM invasion front coincides morphologically
and functionally with ILK, thus pointing to a putative
role of ILK and its associated protein kindlin-2 in the pro-
gression of MPM.13
In 2004, Ahmed and colleagues14 reported the detection
of ILK in the serum of 30 ovarian cancer patients as well as
6 healthy subjects. Because ILK levels rose with tumor
stage and were on average 6-fold higher in the cancer group,
they proposed serum ILK-concentration as a novel marker
for ovarian carcinoma. Despite their promising results, no
research dealing with serum ILK in other cancer types hasery c August 2011
Abbreviations and Acronyms
BCD ¼ benign chest disease
ILK ¼ integrin-linked kinase
MCD ¼ malignant chest disease other than
malignant pleural mesothelioma
MPM ¼ malignant pleural mesothelioma
SMRP ¼ soluble mesothelin–related peptide
Watzka et al General Thoracic Surgeryfollowed their investigations. Supported by our previous
results, as well as those of Ahmed and colleagues,14 we
hypothesized that serum ILK concentration can be used as
a marker for MPM. To test this hypothesis, this study was
designed to determine (1) whether ILK is present in the se-
rum of patients with MPM, (2) whether there are concentra-
tion differences between MPM and control groups
consisting of patients with other malignant chest disease
(MCD) and patients with benign chest disease (BCD), (3)
whether any such differences are strong enough to establish
the parameter of serum ILK as a diagnostic marker for
MPM, and (4) whether the serum ILK concentration pre-
dicts prognosis in patients with MPM.G
T
SMATERIALS AND METHODS
Patient and Sample Recruitment
The study was approved by the institutional review board of the Otto
Wagner Hospital, Vienna, Austria. All participating patients had signed
written, informed consent before donating a vial of venous blood for stor-
age in the thoracic surgical tissue bank (either at NYU Langone Medical
Center in the United States or at the Otto Wagner Hospital in Vienna)
and for subsequent prognostic marker isolation. From this thoracic surgical
tissue bank, frozen serum samples of 46 patients with MPMwere retrieved
(study group); all these blood samples were drawn at the time of surgery,
before the incision. The control group consisted of frozen serum samples
of 98 treatment-naive patients with MCD, and 23 treatment-naive patients
with BCD (Table 1). The frozen serum samples of the study and the control
groups were transferred to the Cardiac Surgery Research Laboratories,
Medical University of Vienna, Vienna, Austria, for subsequent serum
ILK analysis. The laboratory personnel responsible for the serum ILK anal-
ysis were blinded to the identities and to the clinical conditions of the par-
ticipating patients.
Detection of Serum ILK
Ahmed and colleagues14 analyzed serum samples by Western blotting,
and we also used this technique for pilot investigations in our first patients.
Because of that procedure’s limited ability to quantify the exact amount of
protein detected, we chose to design a novel sandwich enzyme-linked im-
munosorbent assay. Standard 96-well microtiter plates (Nunc Immuno
Plates Maxi Sorp C96, 430341; Nunc GmbH & Co KG, Langenselbold,
Germany) were coated with a 2-mg/mL solution of a capture antibody
(Sigma-Aldrich I 783 mouse/anti-ILK/monoclonal; Sigma-Aldrich Han-
dels Gmbh, Vienna, Austria), diluted in Dulbecco phosphate-buffered sa-
line solution (Gibco 14040091; Invitrogen Corporation, Carlsbad, Calif)
and incubated overnight at 4C. After 3 washings with Dulbecco
phosphate-buffered saline solution, a 2% solution of bovine serum albumin
(Sigma-Aldrich I 7030) diluted in Dulbecco phosphate-buffered saline so-
lution was filled into the wells to prevent nonspecific binding reactions. Af-The Journal of Thoracic and Cater an incubation period of 1 hour at room temperature and no washing,
native serum specimens and an ILK-standard curve, consisting of 7 declin-
ing concentrations of recombinant ILK (originating from G.E.H.’s labora-
tory inMelbourne, Australia) diluted in fetal calf serum (100 pg/mL, 10 pg/
mL, 1 pg/mL, 100 ng/mL, 10 ng/mL, 1 ng/mL, 0 ng/mL) were incubated
for 1 hour. Next, we washed the plate 3 times, added the polyclonal detect-
ing antibody (Sigma-Aldrich I 1907, rabbit/anti-ILK, concentration 2 mg/
mL) diluted in a 2% solution of bovine serum albumin, incubated the plate
for 1 hour at room temperature, and washed it 3 times. The same step was
done subsequently for the conjugated antibody (concentration 2 mg/mL) di-
luted in a 2% solution of bovine serum albumin. Finally, we filled each well
with 100 mL of the tetramethylbenzidine-solution (Pierce 34021; Thermo
Fisher Scientific Inc, Rockford, Ill) and stopped the colorimetric reaction
with a 2-mol/L solution of sulfuric acid. Absorbancemeasurement was per-
formed on a multilabel plate reader (Victor3 model 1420; PerkinElmer Inc,
Waltham, Mass) at a wavelength of 450 nm, followed by calculation of se-
rum ILK concentration according to a previously established standard
curve model. ILK enzyme-linked immunosorbent assay was performed
in 2 separate runs for every sample, and additionally in 2 wells per run.
The ILK-specific enzyme-linked immunosorbent assay had an intraclass
correlation coefficient of 0.997 (95% confidence interval, 0.992–1.00) in
its standard curve, and therefore the results were considered to be ex-
tremely reliable.
Clinical Data Gathering
The following clinical and laboratory parameters were recorded: age,
sex, smoking history, diagnosis, histologic subtype of MPM or MCD, as-
bestos exposure for patients with MPM, combined stage of MPM or
MCD, surgical procedures for MPM, disease progression inMPM, survival
status of patients with MPM, survival time with MPM, and the cell lysis
parameters creatine kinase, lactate dehydrogenase, aspartate aminotrans-
ferase, and alanine aminotransferase (from 120 participating patients, in-
cluding 4 patients with MPM). For determination of smoking history,
asbestos exposure, and survival status, the patients were personally con-
tacted and interviewed; all other parameters were retrieved from the clini-
cal charts. All patients with MPM were followed up with computed
tomographic scans every 3 months until death and were also routinely
seen by the surgeons. Progression was documented either by changes in
computed tomographic findings, by new biopsy of growing areas, or by as-
piration cytologic sampling of newly developing ascites. Survival was
scored from the day of the operation until death in months, and all data
are accurate to November 2010. Median potential follow-up for the living
patients was 45 5months (range, 32–83months). The data were censored
at the time of last follow-up.
Patients with BCD were significantly younger than patients with MPM
or MCD (P<.001); however, there was no significant difference in age be-
tween those with MPM and those with MCD (P¼ .42). There were no sig-
nificant differences in sex distribution (P ¼ .32) and smoking history
(P ¼ .11) between the study group and the control groups (Table 1). After
plotting of all serum ILK concentrations, 1 MPM sample was excluded
from further analysis because of an extremely high and outlying serum
ILK concentration (10 times higher than the highest concentration of the
remaining samples), which raised the suspicion of a technical error. A sam-
ple comprising a total of 166 patients was further thus analyzed by statis-
tical means.
Statistical Analysis
Data were analyzed with the SPSS statistical software package (SPSS
Windows, version 17.0; SPSS Inc, an IBM Company, Chicago, Ill). Metric
data, such as survival time or ILK, are expressed as mean  SD when nor-
mally distributed. Skewed metric data are expressed with mean, median,
interquartile range, minimum value, and maximum value. Nominal data
are presented as absolute frequencies and percentages. Correlations be-
tween nominal data were assessed with cross-tabulation and the c2 test,rdiovascular Surgery c Volume 142, Number 2 385
TABLE 1. Demographic characteristics of study and control groups
MPM
(n ¼ 45)
MCD
(n ¼ 98)
BCD
(n ¼ 23)*
Agey (y, mean  SD) 65.5  10.5 62  13.2 51  15.7
Sexz
Male 73.9% 64.3% 56.5%
Female 26.1% 35.7% 43.5%
Smoking historyx
Never smoked 60% 38.8% 47.8%
Smoker 40% 61.2% 52.2%
Asbestos exposure
No 26.7%
Yes 73.3%
Histologic subtype of MPM
Epitheloid 66.7%
Other subtype 33.3%
Histologic subtype of MCD
Squamous NSCLC 21.4%
Nonsquamous NSCLC 41.8%
Miscellaneous MCDk 36.8%
Stage
Stage I and II 40% 45.9%
Stages III and IV 60% 54.1%
Surgical procedures for MPM
Extrapleural pneumonectomy 62.2%
Pleurectomy, decortication 35.6%
Other 2.2%
All data represent percentages of patients unless otherwise stated. MPM, Malignant
pleural mesothelioma; MCD, malignant chest disease other than malignant pleural
mesothelioma; BCD, benign chest disease; NSCLC, non–small cell lung cancer.
*Benign chest disease comprised the following diagnoses: pleural empyema
(n ¼ 10), pneumothorax (n ¼ 3), and miscellaneous (n ¼ 10). yPatients with benign
chest disease were significantly younger than patients in the 2 other groups (P<.001);
there was no significant difference in age between patients with malignant pleural me-
sothelioma and malignant chest disease other than malignant pleural mesothelioma
(P ¼ .42). zThere was no significant difference in sex distribution between the study
group (malignant pleural mesothelioma) and the control groups (P¼ .32). xTherewas
no significant difference in smoking history between the study group (malignant
pleural mesothelioma) and the control groups (P ¼ .11). kMiscellaneous malignant
chest diseases were as follows: thoracic metastatic disease from extrathoracic primary
(n ¼ 20), carcinoid tumors (n ¼ 5), small cell lung cancer (n ¼ 4), mesenchymal
tumors (n¼ 4), thoracic non-Hodgkin lymphoma (n¼ 2), thymus carcinoma (n¼ 1).
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percentage of expected frequencies below 5. Because of outliers, the Spear-
man rank correlation was used to correlate serum ILK with age. To com-
pare the 3 patient groups with respect to serum ILK, a 1-way analysis of
variance with Welch correction and the Games-Howell procedure as post
hoc test were used because of heterogeneous variances. To test the relation-
ships of asbestos exposure, histologic subtypes ofMPM, combined stage ofTABLE 2. Serum integrin-linked kinase determination: Raw values (ng/m
Median IQR Minimum
MPM 8.89 10.5 0
MCD 0.66 1.11 0
BCD 0.78 1.46 0
IQR, Interquartile range; MPM, malignant pleural mesothelioma; MCD, malignant chest d
lignant pleural mesothelioma versus malignant chest disease other than malignant pleural m
pleural mesothelioma versus benign chest disease. zThere was no significant difference in s
small cell lung cancer (P ¼ .95).
386 The Journal of Thoracic and Cardiovascular SurgMPM, disease progression of MPM, and survival status of MPM with se-
rum ILK concentration, t tests were performed. Additionally, a receiver op-
erating characteristic analysis was performed to obtain a cutoff value for
the distinction between MPM and other diseases. Sensitivity, specificity,
negative predictive value, and positive predictive value were calculated
with their 95% confidence intervals. Cox regression was used to assess
the effect of combined stage of MPM, asbestos exposure, histologic sub-
type of MPM, and ILK on survival time. Linear and nonlinear regressions
were performed to test the influences of lactate dehydrogenase, creatine ki-
nase, alanine aminotransferase, and aspartate aminotransferase on serum
ILK. An intraclass correlation coefficient was calculated to assess the qual-
ity of the measurements obtained for standard curves.
RESULTS
The median serum ILK concentration in patients with
MPM was 8.89 ng/mL, significantly higher than in patients
with MCD (0.66 ng/mL) or in those with BCD (0.78 ng/mL,
P<.001); however, the median serum ILK concentrations
were statistically not different between patients with
MCD and BCD (Table 2). There was no correlation of se-
rum ILK with patient age (r ¼0.03, P ¼ .72). Further-
more, there was no relevant correlation of serum ILK with
cell lysis parameters creatine kinase, lactate dehydroge-
nase, aspartate aminotransferase, and alanine aminotrans-
ferase (R2<0.1 always, data not shown). The distribution
of serum ILK concentrations in MPM was highly variable
(Figure 1). In the receiver operating characteristic analysis,
a cutoff value of serum ILK concentration greater than 2.48
ng/mL was found to have a diagnostic sensitivity of 80%,
a specificity of 95%, a positive predictive value of
85.7%, a negative predictive value of 92.7%, and an overall
accuracy of 91% for the distinction between MPM and
MCD or BCD (area under the curve 89.1%, 95% confi-
dence interval 82%–96.1%; Figure 2, Tables 3 and 4).
In univariate analysis, the serum ILK concentration in
MPM was independent of asbestos exposure, histologic
subtype, combined clinical stage, disease progression, and
survival (Table 5). To compensate for multiple interactions
between serum ILK concentration and the well-
establishedMPMprognostic factors of histological subtype,
asbestos exposure, and combined stage, a multivariate
model for the assessment of the effect of serum ILK concen-
tration on MPM survival was constructed. In this model,
only combined stage emerged as a statistically significant
factor for MPM survival, with longer survival in patients
with stage I and II MPM (P ¼ .002). In the multivariateL) in study (malignant pleural mesothelioma) and control groups
Maximum Mean ± SD P value
49.96 10.79  9.89 <.001*
6.3 0.84  1.07 .87y,z
2.7 0.94  0.8
isease other than malignant pleural mesothelioma; BCD, benign chest disease. *Ma-
esothelioma and benign chest disease. yMalignant chest disease other than malignant
erum integrin-linked kinase concentration between squamous and nonsquamous non–
ery c August 2011
FIGURE 1. Box plot of serum integrin-linked kinase (ILK) concentra-
tions. MPM,Malignant pleural mesothelioma, MCD, malignant chest dis-
ease other than malignant pleural mesothelioma, BCD, benign chest
disease.
TABLE 3. Serum integrin-linked kinase determination: Diagnostic
test result for malignant pleural mesothelioma versus presence of
disease
Disease presence
Test result Positive Negative Total
Positive 36 6 42
Negative 9 115 124
Total 45 121 166
Values represent numbers of patients. Threshold value of serum integrin-linked
kinase level was 2.48 ng/mL.
Watzka et al General Thoracic Surgerymodel, there was no statistically significant effect of serum
ILK concentration on MPM survival (Table 6).G
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SDISCUSSION
In this study, we have shown that ILK can be detected in
the serum of patients with MPM, that the concentration of
serum ILK is significantly higher in patients with MPM
than in those with MCD and BCD, that these concentration
differences are strong enough to distinguish with a sensitiv-
ity of 80% and a specificity of 95% between MPM and
MCD or BCD, and that the serum ILK concentration does
not predict the prognosis of patients with MPM.
The mechanism of ILK release into the bloodstream is
not clear. Two main mechanisms could theoretically be re-FIGURE 2. Receiver operating characteristic (ROC) curve for serum
integrin-linked kinase in malignant pleural mesothelioma versus other ma-
lignant chest disease or benign chest disease. Area under the curve is
89.1% (95% confidence interval, 82%–96.1%) at a cutoff value of 2.48
ng/mL.
The Journal of Thoracic and Casponsible for the release of ILK into the bloodstream: (1) in-
creased cell lysis, which is unlikely in our case because at
least in 120 out of 166 samples there was no relevant corre-
lation between serum ILK concentration and cell lysis pa-
rameters, and (2) active secretion, which is also unlikely,
because there is no active secretion of members of the integ-
rin family.15 Many cell types, however, including human
MPM cells, are able to release microvesicles of endosomal
origin, called exosomes, that present the inner side of the
cell membrane on the outside, thus allowing detection of
many membrane-bound cytoplasmic proteins (including
members of the integrin family) on their surface.16,17 To
test the hypothesis of an exosomal origin of serum ILK,
exosome isolation should be done in future studies.
The novel observation of an increased serum ILK concen-
tration in patients with MPM relative to those with
MCD or BCD fits well with the previously described role
of ILK in MPM.11-13 The observation of lower serum
ILK concentration in MCD, however, is somewhat
contradictory to previously published evidence of
a comparably high degree of ILK expression in tissue
specimens of lung adenocarcinoma (79%).18 This is partic-
ularly surprising, because the proportion of adenocarcinoma
(labeled here as nonsquamous non–small cell lung cancer)
was, at 40% of the MCD group, high enough to detect pos-
sible differences in serum ILK concentration. On the other
hand, the MCD group contained a higher proportion of
early-stage cases than did the MPM group. It therefore can-
not be excluded that extensive pleural carcinomatosis of ad-
enocarcinoma (from the lung or metastatic) would yield
serum ILK concentrations as high as those of epitheloid
MPM. Future studies comparing the serum ILK concentra-
tion of all histologic subgroups ofMPMwith stage-matchedTABLE 4. Serum integrin-linked kinase determination: Diagnostic
validity for malignant pleural mesothelioma
% 95% Confidence interval
Sensitivity 80 66.2–89.1
Specificity 95 89.6–97.7
Positive predictive value 85.7 72.2–93.3
Negative predictive value 92.7 86.8–96.1
Accuracy 91 85.6–94.4
Threshold value of serum integrin-linked kinase level was 2.48 ng/mL.
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TABLE 5. Correlation of serum integrin-linked kinase concentration
with clinical parameters of malignant pleural mesothelioma:
Univariate analysis
Serum concentration
(ng/mL) P value
Asbestos exposure .8
No 11  8.93
Yes 10.71  10.35
Histologic subtype .8
Epitheloid 11.07  10.58
Other 10.23  8.66
Combined stage .4
Stages I and II 8.75  7.02
Stages III and IV 12.15  11.34
Disease progression .6
No 9.15  9.55
Yes 11.14  10.05
Survival status .4
Survived 9.24  8.56
Died 11.73  10.66
Concentration values are mean  SD.
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questions.
The diagnostic validity of serum ILK, with its sensitivity
of 80% and its specificity of 95% in the discrimination
between MPM and MCD or BCD, compares favorably
with the diagnostic validity of soluble mesothelin–related
peptides (SMRPs), osteopontin, and megakaryocyte poten-
tiation factor, the 3 currently most investigated biomarkers
of MPM. SMRPs are highly increased in the serum of pa-
tients with MPM.19 The sensitivity of serum SMRP in dif-
ferentiating mesothelioma from benign lesions is 73% to
80%, with a specificity of 82.6% to 95%.20,21 In a recent
prospective study in 538 subjects with occupational
exposure to asbestos, however, a low specificity and
a high number of false-positive values of serum SMRP
were seen.22 In addition, increased levels of serum SMRP
can only be found in the epitheloid but not in the sarcoma-
toid subtype of MPM,19 unlike ILK, which can be found in
all MPM subtypes.11,12 Serum osteopontin levels
discriminate between MPM and asbestos-exposed individ-
uals with a sensitivity of 47% to 77.6% and a specificity
of 85.5% to 95%.21,23 Serum osteopontin is unable,TABLE 6. Correlation of serum integrin-linked kinase concentration
with clinical parameters of malignant pleural mesothelioma:
Multivariate analysis
Hazard ratio for survival P value
Serum integrin-linked kinase
concentration
1.006 .8
Asbestos exposure 2.246 .1
Histologic subtype 1.974 .1
Combined stage* 0.205 .002
*Patients with stage I and II malignant pleural mesothelioma lived longer than pa-
tients with stage III and IV mesothelioma (P ¼ .002).
388 The Journal of Thoracic and Cardiovascular Surghowever, to distinguish between MPM and pleural
metastatic carcinoma.24 Serum megakaryocyte potentiation
factor discriminates with a sensitivity of 74.1% and a spec-
ificity of 90.4% between patients with MPM, patients with
lung cancer, healthy asbestos-exposed subjects, and healthy
adults25 and with a sensitivity of 34% and a specificity of
95% between patients with MPM, healthy control subjects,
and patients with benign asbestos-related disease.21 In sum-
mary, serum ILK seems to have a higher sensitivity and
specificity in discriminating MPM from both MCD and
BCD conditions than either osteopontin or megakaryocyte
potentiation factor.
The finding that the serum concentration of ILK was
prognostic neither for disease progression nor for overall
survival parallels our previous observation that ILK expres-
sion in MPM samples failed to predict prognosis.12 Because
the variance in serum ILK concentration values was so pro-
nounced, however, the statistical power of our analysis re-
garding the prognostic value of serum ILK was low and
thus warrants repetition of the experiments in a much bigger
study population before definitive conclusions can be
drawn. In addition, because of the relatively small sample
size, the lack of statistical difference in serum ILK concen-
trations between early and late stage MPM must also be
interpreted with caution.
Future investigations will need to answer the open ques-
tions. First, it is necessary to ascertain the tissue source of
serum ILK in benign and malignant conditions. In addition
to serum ILK determination, biopsy of the implicated tissue
or disease process is warranted. Furthermore, the normal
value of serum ILK is unknown. To determine a good refer-
ence value, a systematic investigation of serum ILK levels
among healthy subjects and patients with all types of benign
and malignant disease conditions is necessary. Finally, to
evaluate the true prognostic value of serum ILK level in
MPM, it should be determined serially in patients with
MPM—at diagnosis, after therapy, during follow-up—and
values should be analyzed with respect to quantitative mea-
sures of tumor burden (eg, by computed tomographic volu-
metric analysis) or of tumor metabolic activity (eg, by
positron emission tomographic scan).CONCLUSIONS
Our study confirms the presence of ILK in the serum of
patients with MPM and shows for the first time that it is sig-
nificantly higher in these patients than in patients with other
chest diseases. Overall, this study underlines the specific as-
sociation of ILK with MPM and points to several ways in
which this association might be practically exploited in
the future.
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